StreetAlpha
Olema Oncology, Inc. · SEC Form 4

OLMA Insider Trading

From SEC Form 418 trades in 2 yearsUpdated Nov 19, 2026

Every open market buy and sale of Olema Oncology, Inc. stock by its officers, directors and 10% owners over the last two years, straight from SEC Form 4 filings. Insiders are only selling over the last 12 months: $0 bought and $24.7M sold.

← OLMA stock page

Insiders are only selling
Bought, 12 months$00 buys · 0 insiders
Sold, 12 months$24.7M10 sales · 6 insiders
Net−$24.7Mbought minus sold
Planned sales–of sold value, 10b5-1 plans

Buying and selling by month

open market, last 12 months
2025-12: sold $17MDec2026-01: sold $6.5MJanFeb2026-03: sold $952KMarAprMayJun2026-07: sold $291KJulAugSepOctNov
Bought (up)Sold (down)
AI Pro · insider alerts

Get an alert when OLMA insiders trade

We read every Form 4 the moment the SEC posts it and tell you when an OLMA officer, director or 10% owner buys on the open market, or sells $250K or more outside a pre-arranged plan, by email or on your phone.

Insider alerts are part of AI Pro. Start with a free account, then add AI Pro when you want the alerts.

Every OLMA insider trade

2 years · newest first
InsiderTypePriceHeld afterFiled
Jul 24, 2026Cyrus HarmonDirectorSale25,000$11.65$291K702,770Jul 27Form 4
Mar 4, 2026Shawnte MitchellChief Legal OfficerSale40,000$23.79$952K0Mar 5Form 4
Jan 20, 2026Cyrus HarmonDirectorSale10,000$26.88$269K727,770Jan 21Form 4
Jan 15, 2026Shane William Charles KovacsCh. Operating & Financial Off.Sale103,822$28.70$3M139,727Jan 15Form 4
Jan 14, 2026Cyrus HarmonDirectorSale3,489$29.12$102K737,770Jan 16Form 4
Jan 14, 2026David C. MylesCh. Discov. & Non-clin Dev OffSale110,000$28.25$3.1M542,761Jan 14Form 4
Dec 23, 2025Naseem ZojwallaChief Medical OfficerSale269,509$27.94$7.5M4,488Dec 23Form 4
Dec 22, 2025Cyrus HarmonDirectorSale2,881$28.53$82K741,259Dec 29Form 4
Dec 19, 2025Ian T ClarkDirectorSale264,800$29.73$7.9M0Dec 23Form 4
Dec 19, 2025David C. MylesCh. Discov. & Non-clin Dev OffSale51,000$30.46$1.6M551,881Dec 23Form 4
Sep 18, 2025Cyrus HarmonDirectorSale25,000$8.19$205K117,028Sep 18Form 4
Jan 8, 2025Bain Capital Life Sciences Investors, LLC10% ownerBuy300,000$5.76$1.7M7,800,000Jan 13Form 4
Dec 17, 2024G. Walmsley GrahamDirectorSale700,761$6.75$4.7M0Dec 17Form 4
Dec 11, 2024Sean BohenPresident And CEOSale109,502$9.01$986K241,662Dec 11Form 4
Dec 11, 2024Shane William Charles KovacsCh. Operating & Financial Off.Sale35,159$9.01$317K543,549Dec 11Form 4
🔒 3 more trades. Create a free account or sign in to see them all.

OLMA insider trading FAQ

Are OLMA insiders buying or selling?

Insiders are only selling over the last 12 months. 0 insiders bought $0 of OLMA on the open market in 0 trades, and 6 sold $24.7M in 10 trades.

When did an OLMA insider last buy shares?

Bain Capital Life Sciences Investors, LLC (10% owner) bought 300,000 shares for $1.7M on Jan 8, 2025, reported on Jan 13, 2025.

When did an OLMA insider last sell shares?

Cyrus Harmon (Director) sold 25,000 shares for $291K on Jul 24, 2026.

What is a Form 4?

Company officers, directors and owners of more than 10% of the shares must report trades in the company's stock to the SEC on Form 4 within two business days. This page shows open market buys and sales only. Option exercises, stock awards, gifts and shares withheld for taxes are left out, since they are not decisions to buy or sell.

Why do insider sales matter less than buys?

Insiders sell for many reasons, such as taxes, diversification or a home purchase, and many sales are scheduled months ahead under a 10b5-1 trading plan. They buy on the open market mostly when they expect the shares to rise, which is why buying, and especially several insiders buying together, gets more attention.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Trades come from SEC Form 4 filings as reported by the insiders. Insiders have two business days to report, so a trade can be a few days old when it appears. See all insider cluster buys.

From SEC Form 4 filings · Not investment advice